Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak ...

It has been about a month since the last earnings report for Pfizer (PFE). Shares have lost about 4.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.

Second-quarter 2025 Cost of Sales(3) as a percentage of revenues increased by 0.9 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a favorable revision ...

Pfizer (PFE) closed at $24.08 in the latest trading session, marking a -1.19% move from the prior day. The stock trailed the ...

* Indicates calculation not meaningful or results are greater than 100%. First-quarter 2025 Cost of Sales (2) as a percentage of revenues decreased by 2.0 percentage points compared to the prior-year ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets. Pfizer ...

$2.2 billion invested in internal research and development projects, and Approximately $90 million invested in business development transactions. Returning capital directly to shareholders through ...